Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial.

Abstract

BACKGROUND:

Long-term antithyroid drug therapy has become one of the options for treatment of Graves' hyperthyroidism. The aim of this study was to compare thyroid status in those who discontinued methimazole (MMI) treatment after 12.8 years with those who continued MMI as long as 24 years.

METHODS:

Fifty nine patients with Graves' disease on long-term MMI for 14.2 ± 2.9 years were recruited; 32 patients (54%) decided to discontinue MMI and 27 (46%) preferred additional years of MMI treatment. All patients were followed for a mean of 6 additional years.

RESULTS:

Of 27 patients who continued MMI up to 24 years, suppressed serum thyrotropin (TSH) was not observed in any patient after the seventh year of treatment. Serum free thyroxine, triiodothyronine, TSH and TSH receptor antibody concentrations remained normal up to the length of the study. Mean daily dose of MMI to maintain TSH in the reference range decreased gradually and reached to 2.8 ± 1.7 mg by 24 years of MMI treatment. No adverse reaction related to MMI occured during additional years of therapy. In 32 patients who discontinued MMI, hyperthyroidism relapsed in 6 patients (19%), one left follow-up and 25 (78%) remained euthyroid during the study.

CONCLUSIONS:

Long-term low dose MMI treatment may be a lifelong effective and safe therapeutic modality in patients with Graves' hyperthyroidism for prevention of relapse, if studies from other centers confirm findings of this research.

TRIAL REGISTRATION:

IRCT201009224794N1, 2010-10-25. Retrospectively registered. https://www.irct.ir/trial/5143 .

• Authors: Fereidoun Azizi, Hengameh Abdi, Atieh Amouzegar
• Journal: BMC endocrine disorders (BMC Endocr Disord) Vol. 21 Issue 1 Pg. 16 (Jan 14 2021) ISSN: 1472-6823 [Electronic] England
• PMID: 33446181 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antithyroid Agents
• Thyroid Hormones
• Methimazole

Topics

• Adult
• Aged
• Antithyroid Agents (adverse effects, therapeutic use)
• Female
• Follow-Up Studies
• Graves Disease (drug therapy)
• Humans
• Kaplan-Meier Estimate
• Male
• Methimazole (adverse effects, therapeutic use)
• Middle Aged
• Recurrence
• Thyroid Hormones (blood)
• Treatment Outcome